Suchin Virabhak

Pharmaceutical‐embodied technical progress, longevity, and quality of life: drugs as ‘Equipment for Your Health’

Frank R. Lichtenberg, Suchin Virabhak · Managerial and Decision Economics · 2007 · 40 citations

Pharmacy, Pharmaceutical Policy, Health Economics +6

Physicians' prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana.

Suchin Virabhak, Judith A. Shinogle · PubMed · 2005 · 29 citations

Pharmacy, Pharmaceutical Policy, Drug Utilization Review +16

Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US

Sammy Saab, Hélène Parisé, Suchin Virabhak et al. · Journal of Medical Economics · 2016 · 23 citations

Pharmacy, Infectious Diseases, Pharmacoeconomics +17

Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan

Suchin Virabhak, Kikuo Yasui, Kiyotaka Yamazaki et al. · Journal of Medical Economics · 2016 · 22 citations

Pharmacy, Infectious Diseases, Pharmacoeconomics +17

Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States

Sang Kyu Cho, Beenish S. Manzoor, Kavita Sail et al. · PharmacoEconomics · 2020 · 19 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17